CLA for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

CLA for Health & Longevity

Created on 06/21/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

CLA is a natural dairy and beef fat sold as a fat-loss supplement. In people the benefit is small: a modest drop in body fat, clearer alongside exercise, often too minor to matter for an individual. Set against this are real metabolic concerns at higher doses, leaving its overall value genuinely unresolved. (Full Review)

Protocol

Dose
3.0–3.4 g/day
Total CLA; common trial range 1.7–6 g/day
Isomer
Balanced 50:50 mix
c9,t11 + t10,c12 (Tonalin, Clarinol); not purified t10,c12
Timing
Split with meals
2–3 doses with fat-containing food; start low to titrate
Time to effect
Body fat
8–12 weeks
Accrues slowly; no visible change in first few weeks
With exercise
Over 4 weeks
Clearest body-fat signal over interventions longer than four weeks
Overall horizon
Months, not days
Effects build and fade slowly over weeks; judge results over months

Benefits

Contraindications
  • Type 2 diabetes or metabolic syndrome
  • Established or suspected fatty liver disease
  • Pregnancy or breastfeeding
  • Lipoprotein(a) above ~50 mg/dL or strong premature-cardiovascular-disease family history
    •
Key Interactions
  • Antidiabetic drugs (metformin, sulfonylureas such as glipizide, insulin)
  • Blood-thinning and antiplatelet drugs (warfarin, clopidogrel, aspirin)
  • Lipid-lowering drugs (statins such as atorvastatin, fibrates)
  • Over-the-counter NSAIDs (ibuprofen, naproxen)
  • Omega-3 fish oil and other fatty-acid supplements
  • Other fat-loss or thermogenic supplements (caffeine, guarana, green tea extract)
    •

Risk & Side Effects

  • High: Gastrointestinal side effects
    •
  • Medium: Worsening of insulin sensitivity; adverse shifts in blood lipids; elevated markers of oxidative stress and inflammation
    •
  • Low: Liver fat accumulation and enzyme elevation
    •
  • Speculative: Cardiovascular risk from combined lipid and inflammatory effects; pro-diabetic risk in susceptible individuals
    •

Monitoring

Marker Target Why
Fasting glucose 75–85 mg/dL Detects worsening glucose control
Fasting insulin 2–5 µIU/mL Flags rising insulin resistance, a key CLA concern
HbA1c <5.4% Captures medium-term glucose trend
Total cholesterol 160–200 mg/dL CLA can shift cholesterol up or down
HDL cholesterol >55 mg/dL (men), >65 mg/dL (women) CLA may lower HDL
Triglycerides <80 mg/dL CLA can raise triglycerides vs some comparators
Lipoprotein(a) <30 mg/dL CLA may raise this genetic cardiovascular risk marker
ALT (with AST) <25 U/L (men), <20 U/L (women) Screens for CLA-related liver fat or stress
hs-CRP <1.0 mg/L CLA may raise inflammatory and oxidative markers

Cadence: Baseline before starting, recheck at 8–12 weeks, then every 6–12 months if use continues

Qualitative Assessment

  • Waist circumference and how clothing fits
  • Energy levels and exercise performance during training
  • Digestive comfort, a key tolerability signal
  • General sense of well-being and absence of new symptoms such as unusual fatigue
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.